Cargando…
The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis
BACKGROUND: EGFR is among the genes most frequently altered in glioblastoma, with exons 2-7 deletions (EGFRvIII) being among its most common genomic mutations. There are conflicting reports about its prognostic role and it remains unclear whether and how it differs in signaling compared with wildtyp...
Autores principales: | Hoogstrate, Youri, Ghisai, Santoesha A, de Wit, Maurice, de Heer, Iris, Draaisma, Kaspar, van Riet, Job, van de Werken, Harmen J G, Bours, Vincent, Buter, Jan, Vanden Bempt, Isabelle, Eoli, Marica, Franceschi, Enrico, Frenel, Jean-Sebastien, Gorlia, Thierry, Hanse, Monique C, Hoeben, Ann, Kerkhof, Melissa, Kros, Johan M, Leenstra, Sieger, Lombardi, Giuseppe, Lukacova, Slávka, Robe, Pierre A, Sepulveda, Juan M, Taal, Walter, Taphoorn, Martin, Vernhout, René M, Walenkamp, Annemiek M E, Watts, Colin, Weller, Michael, de Vos, Filip Y F, Jenster, Guido W, van den Bent, Martin, French, Pim J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917407/ https://www.ncbi.nlm.nih.gov/pubmed/34608482 http://dx.doi.org/10.1093/neuonc/noab231 |
Ejemplares similares
-
EGFRvIII: the promiscuous mutation
por: Greenall, Sameer A, et al.
Publicado: (2016) -
Efficacy of osimertinib against EGFRvIII+ glioblastoma
por: Chagoya, Gustavo, et al.
Publicado: (2020) -
Development of an EGFRvIII specific recombinant antibody
por: Gupta, Puja, et al.
Publicado: (2010) -
Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII(+)PTEN(−) glioblastoma in vivo
por: Xu, Wen, et al.
Publicado: (2016) -
Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma
por: Padfield, Emily, et al.
Publicado: (2015)